The global Hormone Replacement Therapy market is projected to attain a value of US$ 35.86 Billion by 2032. In 2023, the worldwide hormone replacement therapy market was appraised to be worth US$ 20.91 Billion, and it increased at a compound annual growth rate of 6.18% from 2024 to 2032.
The World Population Prospects 2022 report reveals that the global population is expected to increase significantly soon. The United Nations predicts that by 2030, the world's population could reach 8.5 Billion, The world population by 2050 and 2100. Women's bodies are susceptible to hormonal changes, which can cause a various of issues such as weight gain, memory decline, fatigue, low libido, aging appearance, and muscle loss.
The NHSBSA Statistics and Data Science department reported that in 2022-23, 11 million hormone replacement therapy (HRT) items were prescribed in England, an increase of 47% from the previous year. Approximately 2.3 million patients received HRT prescriptions, a 29% increase from the prior year. The report also highlighted that patients in the least deprived areas were prescribed HRT items more than twice as frequently as those in the most deprived areas. Finally, the proportion of HRT prescriptions exempt from prescription charges increased from April 2023, a reversal of the downward trend observed since 2015-16.
The rising prevalence of menopausal symptoms and increased awareness of post-menopausal challenges are key drivers advancing the global HRT market. China's economic development and policies have increased women's awareness of self-care and participation in physical examinations. Studies have shown that menopausal symptoms are prevalent in women, with rates as high as 73.8% in community groups and perimenopausal women in rural India being more prone to symptoms compared to pre-menopausal and post-menopausal women.
The prevalence of hormonal imbalances and related disorders is increasing, leading to a rise in demand for hormone replacement therapy. This therapy involves administering synthetic or natural hormones to replace deficient levels of hormones in the body. It is particularly beneficial for individuals experiencing symptoms like hot flashes, mood swings, and reduced libido. The growing awareness of its benefits and the availability of advanced hormone replacement therapies are expected to drive market growth.
2. Human Growth Hormone Replacement Therapy
3. Thyroid Hormone Replacement Therapy
4. Testosterone Hormone Replacement Therapy
5. Progestogen Hormone Replacement Therapy
2. Hypothyroidism
3. Male Hypogonadism
4. Growth Hormone Deficiency
5. Others
2. Parental
3. Others
2. Retail Pharmacies & Stores
3. Online Pharmacies
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
2. Bayer AG
3. Eli Lilly & Company
4. Novartis AG
5. Novo Nordisk A/S
6. Pfizer Inc.
7. Abbvie Inc. (Allergan plc)
8. Teva Pharmaceutical Industries Ltd
9. Dr. Reddy’s Laboratories Ltd
Global Hormone Replacement Therapy Analysis
Hormone replacement therapy (HRT) uses medications that contain female hormones to replenish the estrogen that the body no longer produces after menopause. HRT can help alleviate menopause symptoms such as hot flashes and night sweats. It can also minimize bone loss and fractures in postmenopausal women. HRT subtypes are based on naturally occurring hormones like progesterone, estrogen, and testosterone. Menopause is a frequently reported consequence of age-related hormonal changes occurring around the age of 50.The World Population Prospects 2022 report reveals that the global population is expected to increase significantly soon. The United Nations predicts that by 2030, the world's population could reach 8.5 Billion, The world population by 2050 and 2100. Women's bodies are susceptible to hormonal changes, which can cause a various of issues such as weight gain, memory decline, fatigue, low libido, aging appearance, and muscle loss.
The NHSBSA Statistics and Data Science department reported that in 2022-23, 11 million hormone replacement therapy (HRT) items were prescribed in England, an increase of 47% from the previous year. Approximately 2.3 million patients received HRT prescriptions, a 29% increase from the prior year. The report also highlighted that patients in the least deprived areas were prescribed HRT items more than twice as frequently as those in the most deprived areas. Finally, the proportion of HRT prescriptions exempt from prescription charges increased from April 2023, a reversal of the downward trend observed since 2015-16.
Global Hormone Replacement Therapy Trends
Rising R&D and product approvals are expected to aid the growth of the hormonal therapy market. Ascendis Pharma A/S's drug SKYTROFA received market authorization in January 2022 for treating growth hormone disorders in children and adolescents. In November 2021, I-MAB Biopharma Co., Ltd. partnered with Jumpcan Pharmaceutical Group to market and develop eftansomatropin alfa, named TJ101, in China to treat pediatric growth hormone insufficiency.The rising prevalence of menopausal symptoms and increased awareness of post-menopausal challenges are key drivers advancing the global HRT market. China's economic development and policies have increased women's awareness of self-care and participation in physical examinations. Studies have shown that menopausal symptoms are prevalent in women, with rates as high as 73.8% in community groups and perimenopausal women in rural India being more prone to symptoms compared to pre-menopausal and post-menopausal women.
The prevalence of hormonal imbalances and related disorders is increasing, leading to a rise in demand for hormone replacement therapy. This therapy involves administering synthetic or natural hormones to replace deficient levels of hormones in the body. It is particularly beneficial for individuals experiencing symptoms like hot flashes, mood swings, and reduced libido. The growing awareness of its benefits and the availability of advanced hormone replacement therapies are expected to drive market growth.
United States Hormone Replacement Therapy Market
The US has the biggest market for Hormone Replacement Therapy, with rising utilization among patients over 35 years old. The availability of intensified drugs and an increase in the target population drive market growth. The rise in the release of generic hormone replacement therapy medicines and advances in drug delivery technologies are also contributing factors. NIH reports almost half of post-menopausal US women have used HRT. 1.3 Million American women enter menopause each year. Conjugated equine estrogens/bazedoxifene tablets are available for menopausal VMS treatment and osteoporosis prevention. The American Thyroid Association has predicted that over 12% of the US population will experience a thyroid disorder during their lifetime, affecting almost 20 million Americans every year. This high incidence of thyroid hormone imbalance is expected to boost the studied market in the region. Additionally, in June 2022, Astellas Pharma Inc. submitted a New Drug Application for fezolinetant, seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause.Hormone Replacement Therapy Market Company News
Some of the prominent player in the Hormone Replacement Therapy Market are Abbott Laboratories, Bayer AG, Eli Lilly & Company, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Abbvie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd, and Dr. Reddy’s Laboratories Ltd.- In February 2023, Korea’s Ministry of Food and Drug Safety approved Pfizer’s NGENLA for treating growth hormone deficiency.
- Pfizer Inc. finished obtaining Arena Pharmaceuticals in 2022. This acquisition will prompt an upgrade in the portfolio to dermatology, cardiology, gastroenterology, and so forth.
- In February 2022, MHLW of Japan approved NGENLA of Pfizer, Inc., and OPKO, a long-lasting pediatric growth hormone deficiency treatment. This strategic initiative helps companies expand their customer base in different geographies and boost their revenue.
- In June 2022, Halozyme Therapeutics launched TLANDO, an oral treatment to replace endogenous testosterone in adult males with a deficiency or absence.
- In August 2022, Akorn received FDA approval to launch its Generic-Cetrorelix Acetate Injection (0.25 mg). Cetrorelix blocks premature ovulation during ovarian stimulation, making eggs more suitable for fertilization.
Product Type - Global Hormone Replacement Therapy Market breakup in 5 viewpoints:
1. Estrogen Hormone Replacement Therapy2. Human Growth Hormone Replacement Therapy
3. Thyroid Hormone Replacement Therapy
4. Testosterone Hormone Replacement Therapy
5. Progestogen Hormone Replacement Therapy
Disease Type - Global Hormone Replacement Therapy Market breakup in 5 viewpoints:
1. Menopause2. Hypothyroidism
3. Male Hypogonadism
4. Growth Hormone Deficiency
5. Others
Route of Administration - Global Hormone Replacement Therapy Market breakup in 3 viewpoints:
1. Oral2. Parental
3. Others
Distribution Channels - Global Hormone Replacement Therapy Market breakup in 3 viewpoints:
1. Hospitals Pharmacies2. Retail Pharmacies & Stores
3. Online Pharmacies
Country - Global Hormone Replacement Therapy Market breakup of 25 Countries Covered in the Report:
1. North America1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the key players have been covered from 3 viewpoints:
- Overview
- Recent Development
- Revenue Analysis
Company Analysis:
1. Abbott Laboratories2. Bayer AG
3. Eli Lilly & Company
4. Novartis AG
5. Novo Nordisk A/S
6. Pfizer Inc.
7. Abbvie Inc. (Allergan plc)
8. Teva Pharmaceutical Industries Ltd
9. Dr. Reddy’s Laboratories Ltd
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary5. Global Hormone Replacement Therapy Market
4. Market Dynamics
6. Market Share - Global Hormone Replacement Therapy Market
7. Therapy Type - Global Hormone Replacement Therapy Market
8. Disease Type - Global Hormone Replacement Therapy Market
9. Route of Administration - Global Hormone Replacement Therapy Market
10. Distribution Channel - Global Hormone Replacement Therapy Market
11. Country - Global Hormone Replacement Therapy Market
12. Porter’s Five Analysis - Global Hormone Replacement Therapy Market
13. SWOT Analysis - Global Hormone Replacement Therapy Market
14. Company Analysis
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Bayer AG
- Eli Lilly & Company
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Abbvie Inc. (Allergan plc)
- Teva Pharmaceutical Industries Ltd
- Dr. Reddy’s Laboratories Ltd
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 230 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 20.91 Billion |
| Forecasted Market Value ( USD | $ 35.86 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
